Britannia Life Sciences Inc.
BLSIF
$0.04
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 40.21% | -- | -- | 88.83% | -62.37% |
| Total Depreciation and Amortization | 1.77% | -- | -- | 259.09% | 2.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -309.29% | -- | -- | -84.84% | 160.42% |
| Change in Net Operating Assets | 100.59% | -- | -- | 159.91% | -35.72% |
| Cash from Operations | 54.08% | -- | -- | 649.39% | 594.74% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,908.97% | -- | -- | 5.82% | -9.05% |
| Cash from Investing | -1,908.97% | -- | -- | -7.28% | -9.05% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -1.68% | -- | -- | -2,344.68% | -11.37% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -11.25% |
| Cash from Financing | -1.85% | -- | -- | -389.83% | 137.26% |
| Foreign Exchange rate Adjustments | 179.07% | -- | -- | -103.30% | 254.26% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -288.37% | -- | -- | -94.54% | 140.61% |